Killer to cure: Expression and production costs calculation of tobacco plant‐made cancer‐immune checkpoint inhibitors

Abstract

SummaryImmune checkpoint inhibitors (ICIs) have achieved huge clinical success. However, many still have limited response rates, and are prohibitively costly. There is a need for effective and affordable ICIs, as well as local manufacturing capacity to improve accessibility, especially to low‐to‐middle income countries (LMICs). Here, we have successfully expressed three key ICIs (anti‐PD‐1 Nivolumab, anti‐NKG2A Monalizumab, and anti‐LAG‐3 Relatimab) transiently in Nicotiana benthamiana and Nicotiana tabacum plants. The ICIs were expressed with a combination of different Fc regions and glycosylation profiles. They were characterized in terms of protein accumulation levels, target cell binding, binding to human neonatal Fc receptors (hFcRn), human complement component C1q (hC1q) and various Fcγ receptors, as well as protein recovery during purification at 100 mg‐ and kg‐scale. It was found that all ICIs bound to the expected target cells. Furthermore, the recovery during purification, as well as Fcγ receptor binding, can be altered depending on the Fc region used and the glycosylation profiles. This opens the possibility of using these two parameters to fine‐tune the ICIs for desired effector functions. A scenario‐based production cost model was also generated based on two production scenarios in hypothetical high‐ and low‐income countries. We have shown that the product accumulation and recovery of plant production platforms were as competitive as mammalian cell‐based platforms. This highlights the potential of plants to deliver ICIs that are more affordable and accessible to a widespread market, including LMICs.